265 related articles for article (PubMed ID: 29608923)
1. Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia.
Newcombe AA; Gibson BES; Keeshan K
Exp Hematol; 2018 Jul; 63():1-11. PubMed ID: 29608923
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
Ungerstedt JS
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic mechanisms in AML - a target for therapy.
Oki Y; Issa JP
Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.
Kim TK; Gore SD; Zeidan AM
Semin Hematol; 2015 Jul; 52(3):172-83. PubMed ID: 26111464
[TBL] [Abstract][Full Text] [Related]
5. Molecularly targeted therapy in acute myeloid leukemia.
Gill H; Leung AY; Kwong YL
Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy restores normal hematopoiesis in a zebrafish model of NUP98-HOXA9-induced myeloid disease.
Deveau AP; Forrester AM; Coombs AJ; Wagner GS; Grabher C; Chute IC; Léger D; Mingay M; Alexe G; Rajan V; Liwski R; Hirst M; Steigmaier K; Lewis SM; Look AT; Berman JN
Leukemia; 2015 Oct; 29(10):2086-97. PubMed ID: 26017032
[TBL] [Abstract][Full Text] [Related]
9. MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML.
Larmonie NSD; Arentsen-Peters TCJM; Obulkasim A; Valerio D; Sonneveld E; Danen-van Oorschot AA; de Haas V; Reinhardt D; Zimmermann M; Trka J; Baruchel A; Pieters R; van den Heuvel-Eibrink MM; Zwaan CM; Fornerod M
Oncogene; 2018 Jan; 37(1):107-115. PubMed ID: 28892045
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.
Xu QY; Yu L
Chin Med J (Engl); 2020 Mar; 133(6):699-715. PubMed ID: 32044818
[TBL] [Abstract][Full Text] [Related]
11. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Stahl M; Gore SD; Vey N; Prebet T
Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
[TBL] [Abstract][Full Text] [Related]
12. Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications.
Yang X; Wong MPM; Ng RK
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31527484
[TBL] [Abstract][Full Text] [Related]
13. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.
Prokocimer M; Molchadsky A; Rotter V
Blood; 2017 Aug; 130(6):699-712. PubMed ID: 28607134
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
Ferrara FF; Fazi F; Bianchini A; Padula F; Gelmetti V; Minucci S; Mancini M; Pelicci PG; Lo Coco F; Nervi C
Cancer Res; 2001 Jan; 61(1):2-7. PubMed ID: 11196162
[TBL] [Abstract][Full Text] [Related]
15. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.
Wouters BJ; Delwel R
Blood; 2016 Jan; 127(1):42-52. PubMed ID: 26660432
[TBL] [Abstract][Full Text] [Related]
16. Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
[TBL] [Abstract][Full Text] [Related]
17. Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies.
Lee E; Koh Y; Hong J; Eom HS; Yoon SS
J Korean Med Sci; 2021 Apr; 36(13):e85. PubMed ID: 33821592
[TBL] [Abstract][Full Text] [Related]
18. New strategies for relapsed acute myeloid leukemia: fertile ground for translational research.
Dinner SN; Giles FJ; Altman JK
Curr Opin Hematol; 2014 Mar; 21(2):79-86. PubMed ID: 24419335
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
[TBL] [Abstract][Full Text] [Related]
20. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
Hou HA; Tien HF
Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
